The American Heart Association is backing an AI startup aimed at improving detection of hard-to-diagnose conditions like cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The company, named Ultromics, offers a platform that analyzes routine echocardiograms to help clinicians catch disease earlier, particularly for women who are more likely to be missed.
The post AHA Invests in AI that Tackles Cardiology’s Gender Bias Problem appeared first on MedCity News.
